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Abstract. Background/Aim: Second primary tumors (SPTs)
often occur, either synchronous or metachronous. Struma
ovarii is a rare ovarian tumor represented by thyroid tissue
in the ovary. Among other factors, production of thyroid
hormones by the tumor or a shared genetic predisposition
can further influence the development of SPTs. The
occurrence of SPT, either synchronous or metachronous,
following a long follow-up, has never been considered
extensively. Patients and Methods: We analyzed the
Surveillance, Epidemiology, and End Results (SEER)
database from 1973 to 2011 to follow-up all the cases of
malignant struma ovarii in an effort of calculate the
occurrence of SPTs in this cohort of patients. Results: We
identified 21 patients with malignant struma ovarii in the
period between January 1973 and December 2011. In a
follow-up period of 219.57 person-years, 3 patients had SPT.
One patient had synchronous thyroid sclerosing carcinoma,
1 patient had metachronous papillary adenocarcinoma with
a latent time of 7 years and 1 patient had synchronous
salivary ductal carcinoma. Conclusion: Up to date, only
thyroid synchronous tumors have been reported in the
literature. A synchronous and a metachronous thyroid tumor,
plus a synchronous salivary gland tumor, were found. A
significant association between malignant struma ovarii and
thyroid/salivary gland cancer is herein demonstrated.
Second primary tumors (SPTs) often occur. The time lag
between the first and second malignant transformation is
variable. Two or more primary carcinomas can coexist at the
time of diagnosis (synchronous) or develop consequently
(metachronous), sometimes years after resection of the first
primary.
Struma ovarii is a rare ovarian tumor comprising less than
2% of ovarian teratomas (1), with only 5% of these being
malignant tumors (2). By definition, at least 50% of the
tumor mass must be represented by thyroid tissue (3).
Diagnosis of struma ovarii is often incidental after
histological examination of surgically resected ovarian mass
as clinical presentation is usually asymptomatic, although it
can occur with pelvic pain (4), abdominal swelling (5),
hyperthyroidism (6), ascites (7) or pseudo-Meigs syndrome
(8). Both Graves' disease that Hashimoto's thyroiditis have
been diagnosed in some cases simultaneously with this
cancer (9-11). Associated tumors have been sporadically
described in the ovary (12), breast (13) and thyroid gland as
follicular and papillary carcinoma (9, 14-16). 
The occurrence of SPT, either synchronous or
metachronous, following a long follow-up, has never been
studied.
We analyzed the Surveillance, Epidemiology, and End
Results (SEER) database (17) to follow-up all the cases of
malignant struma ovarii in an effort to calculate the
occurrence of SPT in this cohort of patients.
Patients and Methods 
We used the incidence - SEER 9 Regs Research data (17). The
SEER database is sponsored by the National Cancer Institute and
has reported cancer incidence and survival since its institution in
1973. 
It is a population-based registry that covers approximately 26%
of the United States population and captures 98% of all cancer cases
in its surveyed geographic area. The SEER registry was examined
from 1973 to 2011 and cases of malignant struma ovarii were
identified.
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The database contains information on patient demographics,
primary cancer site, histology, methods of diagnostic confirmation,
treatment regimens (including surgery and radiation therapy) and
year of death. Institutional Review Board approval was not required
for this study as the SEER database is free of any sensitive patient
information or identifiers. 
The SEER 9 registries are Atlanta, Connecticut, Detroit, Hawaii,
Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound
and Utah. Data are available for cases diagnosed from 1973 and
later for these registries with the exception of Seattle-Puget Sound
and Atlanta. The Seattle-Puget Sound and Atlanta registries joined
the SEER program in 1974 and 1975, respectively.
We used the SEER*Stat software (18) to estimate the incidence
of SPT in the struma ovarii cases. 
For the identification of SPTs, SEER takes account of histology,
site, laterality and time since initial diagnosis to identify multiple
primary cancers (19, 20).
In the distinction between synchronous and metachronous SPT,
we used the widely-accepted criteria established by Warren and
Gates (21) as follows: synchronous tumors were defined as second
primary tumors that were diagnosed within 6 months of the first
primary tumor; metachronous cancers were defined as those that
were detected after an interval of more than 6 months.
The SEER*Stat software (18) gives also the ratio between
observed/expected (O/E) cases, calculating significance levels with
the Fisher’s exact test.
A p-value less that 0.05 was considered statistically significant.
Results
We identified 21 patients with malignant struma ovarii in the
period between January 1973 and December 2011. In a follow-
up period of 219.57 person-years, 3 patients had SPT (Table I). 
One patient had synchronous thyroid sclerosing carcinoma,
1 patient had metachronous papillary adenocarcinoma with a
latent time of 7 years and 1 patient had synchronous salivary
ductal carcinoma.
All patients had surgery of the primary site without
subsequent radiotherapy.
The O/E ratio to the general population was 41.88 for
thyroid cancers and 344.10 for salivary gland tumors, both
of them resulted to be statistically significant (Table II).
The risk of all solid tumors, in general, was not augmented
when compared to the general population (Table II).
Discussion
We found a significant association between malignant struma
ovarii and thyroid/salivary gland cancer. 
Up until now, only thyroid synchronous tumors have been
reported in the literature (9, 14-16). We found a synchronous
and a metachronous thyroid tumor, plus a synchronous
salivary gland tumor. 
The current, generally accepted, main theories have
proposed the co-occurrence of struma ovarii and thyroid cancer
as a mutagenic trigger causing independent genetic events (14).
The risk of further primary cancers might be due to
persisting effects of genetic and behavioural risk factors,
long term side-effects of chemo- and radiotherapy, as well
as increased diagnostic sensitivity.
We suppose that a common genetic mutagen can affect
different body sites to develop similar tumoral mutations.
One can also speculate that the thyroid hormonal production
by the ovarian tumor can further influence the development
of other tumors in the subsequent years. Treatment for struma
ovarii involves surgical resection due to the risk of malignant
degeneration or hyperthyroidism. 
Due to the rarity of thyroid cancer arising within struma
ovarii, optimal management has not yet been defined (16).
Surgical management of the primary tumor and the thyroid
gland, as well as the potential indications for adjuvant
treatment, have not been standardized. 
Pelvic management includes unilateral cystectomy as main
procedure. Eventually, the surgeon can decide to perform
unilateral salpingo-oophorectomy or total abdominal
hysterectomy with bilateral salpingo-oophorectomy, depending
on the grade of the tumor and the patient’s fertility wellness.
When extra-ovarian extension or distant metastases are
present, total thyroidectomy may be performed to facilitate
radioactive iodine (RAI) therapy. 
The role of thyroidectomy and RAI in localized, non-
metastatic struma ovarii thyroid cancer is not well-defined,
since the natural history of the disease is not yet well-known
(22). The few studies available about follow-up of struma
ovarii have showed an overall good prognosis and a low
percentage of recurrence of well-differentiated thyroid cancer
arising in struma ovarii (16, 23), even if very aggressive
forms have been described (24). 
Our finding of two second primary thyroid tumors
coincidentally or after struma ovarii, reinforces the side of an
aggressive management comprehending a thyroidectomy (25).
The association with a salivary gland tumor is new and
further studies are needed to assess the relationship between
these two tumors. There seems to be little evidence of the
direct relationship between the function of the thyroid gland
and the salivary glands from experiments in rats and mice
(26, 27). Thyroid diagnostic imaging at the time of the
diagnosis of struma ovarii is very important in order to find
any other synchronous tumor present in other locations or
any metastases. This can be performed by 124I-positron
emission tomography/computed tomography (PET/CT).
Magnetic resonance (MR) imaging and ultrasound (US) are
useful to unearth pathological structures located in soft
tissues (28-30). In addition, a check-up for synchronous
salivary gland tumor could be of certain importance.
In our opinion, the extension of surveillance for a longer
follow-up period should be carefully evaluated in every patient
affected by struma ovarii, in search of subsequent development
of thyroid cancers or other tumors after struma ovarii. 
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